Karyopharm Therapeutics Inc. (NASDAQ:KPTI) headquartered in Newton, will host a conference call for the investment community to discuss the 3Q20 financial results on 2nd November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.karyopharm.com
Earnings Expectation
Karyopharm Therapeutics Inc. is reporting third quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, KPTI is expected to report 3Q20 loss of $ 0.72 per share from revenue of $ 21.45 million.
For the full year, analysts anticipate top line of $ 110.03 million, while looking forward to loss of $ 2.75 per share bottom line.
Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor), which has received approval from the Food and Drug Administration in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma, as well as is under review by the European Medicines Agency.
